$CELU
Celularity Inc

2024 Q3 Form 10-Q Financial Statement

#000095017024133799 Filed on December 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $9.296M
YoY Change 145.54%
Cost Of Revenue $3.883M
YoY Change 7.8%
Gross Profit $5.413M
YoY Change 2841.85%
Gross Profit Margin 58.23%
Selling, General & Admin $12.65M
YoY Change 17.7%
% of Gross Profit 233.7%
Research & Development $3.915M
YoY Change -24.45%
% of Gross Profit 72.33%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $16.57M
YoY Change 3.99%
Operating Profit -$11.53M
YoY Change -88.39%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$4.571M
YoY Change -184.96%
Pretax Income -$16.10M
YoY Change -82.85%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$16.10M
YoY Change -82.85%
Net Earnings / Revenue -173.17%
Basic Earnings Per Share -$0.73
Diluted Earnings Per Share -$0.73
COMMON SHARES
Basic Shares Outstanding 21.98M
Diluted Shares Outstanding 21.98M

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $133.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $3.963M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.50M
YoY Change -12.1%
LONG-TERM ASSETS
Property, Plant & Equipment $63.21M
YoY Change -10.53%
Goodwill $7.347M
YoY Change 0.0%
Intangibles $9.624M
YoY Change -16.7%
Long-Term Investments
YoY Change
Other Assets $287.0K
YoY Change -18.93%
Total Long-Term Assets $114.3M
YoY Change -18.73%
TOTAL ASSETS
Total Short-Term Assets $14.50M
Total Long-Term Assets $114.3M
Total Assets $128.8M
YoY Change -18.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.40M
YoY Change 19.09%
Accrued Expenses
YoY Change
Deferred Revenue $3.693M
YoY Change 50.24%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $76.17M
YoY Change -10.0%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $283.0K
YoY Change -4.39%
Total Long-Term Liabilities $283.0K
YoY Change -4.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $76.17M
Total Long-Term Liabilities $283.0K
Total Liabilities $111.6M
YoY Change -12.12%
SHAREHOLDERS EQUITY
Retained Earnings -$886.4M
YoY Change 4.12%
Common Stock $2.000K
YoY Change -89.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.28M
YoY Change
Total Liabilities & Shareholders Equity $128.8M
YoY Change -18.04%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$16.10M
YoY Change -82.85%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001752828
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2024#AccountingStandardsUpdate201613Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38914
dei Entity Registrant Name
EntityRegistrantName
Celularity Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1702591
dei Entity Address Address Line1
EntityAddressAddressLine1
170 Park Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
dei City Area Code
CityAreaCode
(908)
dei Local Phone Number
LocalPhoneNumber
768-2170
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22484239
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
227000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6059000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
5837000
CY2024Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
8770000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
10046000
CY2024Q3 celu Promissory Notes Receivable
PromissoryNotesReceivable
0
CY2023Q4 celu Promissory Notes Receivable
PromissoryNotesReceivable
2072000
CY2024Q3 us-gaap Inventory Net
InventoryNet
3963000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5753000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1636000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1695000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
14502000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19793000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
63208000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67828000
CY2024Q3 us-gaap Goodwill
Goodwill
7347000
CY2023Q4 us-gaap Goodwill
Goodwill
7347000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9624000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11001000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10865000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10990000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10163000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
9936000
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
12844000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
16657000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
287000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
337000
CY2024Q3 us-gaap Assets
Assets
128840000
CY2023Q4 us-gaap Assets
Assets
143889000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
15400000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14144000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14466000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7580000
CY2024Q3 celu Accrued Research And Development Software
AccruedResearchAndDevelopmentSoftware
0
CY2023Q4 celu Accrued Research And Development Software
AccruedResearchAndDevelopmentSoftware
3500000
CY2024Q3 us-gaap Shortterm Debt Fair Value
ShorttermDebtFairValue
3695000
CY2023Q4 us-gaap Shortterm Debt Fair Value
ShorttermDebtFairValue
17223000
CY2024Q3 celu Short Term Debt Unaffilliated
ShortTermDebtUnaffilliated
3695000
CY2023Q4 celu Short Term Debt Unaffilliated
ShortTermDebtUnaffilliated
19331000
CY2024Q3 celu Short Term Debt Related Parties
ShortTermDebtRelatedParties
38915000
CY2023Q4 celu Short Term Debt Related Parties
ShortTermDebtRelatedParties
19909000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3693000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2834000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
76169000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
67298000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2639000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3186000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1606000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1606000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26451000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26177000
CY2024Q3 celu Warrant Liability
WarrantLiability
4403000
CY2023Q4 celu Warrant Liability
WarrantLiability
4359000
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
9000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
9000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
283000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
294000
CY2024Q3 us-gaap Liabilities
Liabilities
111560000
CY2023Q4 us-gaap Liabilities
Liabilities
102929000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
730000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
730000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21984614
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21984614
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19378192
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19378192
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
903670000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
882749000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-886390000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-841791000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17280000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
40960000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128840000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143889000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9296000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3786000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36088000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10659000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3915000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5182000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13558000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30737000
CY2024Q3 celu Software Cease Use Costs
SoftwareCeaseUseCosts
0
CY2023Q3 celu Software Cease Use Costs
SoftwareCeaseUseCosts
243000
celu Software Cease Use Costs
SoftwareCeaseUseCosts
0
celu Software Cease Use Costs
SoftwareCeaseUseCosts
24161000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12650000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10748000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42585000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37508000
CY2024Q3 celu Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
0
CY2023Q3 celu Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
0
celu Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
0
celu Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
-104339000
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
82714000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
112347000
CY2024Q3 celu In Process Research And Development Impairment
InProcessResearchAndDevelopmentImpairment
0
CY2023Q3 celu In Process Research And Development Impairment
InProcessResearchAndDevelopmentImpairment
0
celu In Process Research And Development Impairment
InProcessResearchAndDevelopmentImpairment
0
celu In Process Research And Development Impairment
InProcessResearchAndDevelopmentImpairment
107800000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
375000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
553000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1377000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1640000
CY2024Q3 celu Operating Income Costs And Expenses
OperatingIncomeCostsAndExpenses
20823000
CY2023Q3 celu Operating Income Costs And Expenses
OperatingIncomeCostsAndExpenses
103042000
celu Operating Income Costs And Expenses
OperatingIncomeCostsAndExpenses
65166000
celu Operating Income Costs And Expenses
OperatingIncomeCostsAndExpenses
216261000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11527000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-99256000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29078000
us-gaap Operating Income Loss
OperatingIncomeLoss
-205602000
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
77000
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
23000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
254000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
205000
CY2024Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1752000
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
971000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
4452000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2352000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-714000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5187000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1156000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6788000
CY2024Q3 celu Change In Fair Value Of Debt
ChangeInFairValueOfDebt
708000
CY2023Q3 celu Change In Fair Value Of Debt
ChangeInFairValueOfDebt
-2003000
celu Change In Fair Value Of Debt
ChangeInFairValueOfDebt
694000
celu Change In Fair Value Of Debt
ChangeInFairValueOfDebt
354000
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3908000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2024Q3 celu Other Nonoperating Income Expenses
OtherNonoperatingIncomeExpenses
-2902000
CY2023Q3 celu Other Nonoperating Income Expenses
OtherNonoperatingIncomeExpenses
-862000
celu Other Nonoperating Income Expenses
OtherNonoperatingIncomeExpenses
-5565000
celu Other Nonoperating Income Expenses
OtherNonoperatingIncomeExpenses
-4527000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4571000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5380000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15521000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-240000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16098000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-93876000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44599000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-205842000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16098000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-93876000
us-gaap Net Income Loss
NetIncomeLoss
-44599000
us-gaap Net Income Loss
NetIncomeLoss
-205842000
CY2024Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
-2000
CY2023Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
0
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
-2000
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
2541000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2541000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16100000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93876000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44601000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-203301000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.98
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.86
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21976339
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21976339
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18831713
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18831713
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21756498
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21756498
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17353605
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17353605
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
40960000
CY2024Q1 celu Issuance Of Common Stock For Debt Extension And Commitment Fee
IssuanceOfCommonStockForDebtExtensionAndCommitmentFee
317000
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
357000
CY2024Q1 celu Issuance Of Common Stock Value To Palantir As Consideration For Settlement Agreement
IssuanceOfCommonStockValueToPalantirAsConsiderationForSettlementAgreement
50000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2966000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-22013000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
31245000
CY2024Q2 celu Issuance Of Common Stock Value To Palantir As Consideration For Settlement Agreement
IssuanceOfCommonStockValueToPalantirAsConsiderationForSettlementAgreement
125000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2990000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-6488000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
27811000
CY2024Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
73000
CY2024Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
-2000
CY2024Q3 celu Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability Classified To Equity Classified
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
2970000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2672000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-16098000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
17280000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
198901000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
300000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3358000
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
53000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
136000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
274000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3988000
CY2023Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
2810000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-64017000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
155628000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
272000
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
33000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3856000
CY2023Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
-269000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-47949000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
118501000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
814000
CY2023Q3 celu Stock Issued During Period Values Short Term Debt Maturity Extension
StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension
712000
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1000
CY2023Q3 celu Fair Value Of Warrant Modification For Professional Services
FairValueOfWarrantModificationForProfessionalServices
403000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3598000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-93876000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
30247000
us-gaap Profit Loss
ProfitLoss
-44599000
us-gaap Profit Loss
ProfitLoss
-205842000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6046000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7028000
celu Non Cash Lease Expense
NonCashLeaseExpense
125000
celu Non Cash Lease Expense
NonCashLeaseExpense
-62000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
222000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
456000
celu Provision For Inventory Obsolescence
ProvisionForInventoryObsolescence
-50000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1156000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6788000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
112347000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
107800000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
8628000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
11442000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-104339000
celu Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
3000000
celu Issuance Of Common Stock For Stem Cells To Be Used In Research And Development
IssuanceOfCommonStockForStemCellsToBeUsedInResearchAndDevelopment
1000000
celu Issuance Of Common Stock To Palantir As Consideration For Settlement Agreement
IssuanceOfCommonStockToPalantirAsConsiderationForSettlementAgreement
175000
celu Issuance Of Common Stock Relating To Debt Extension And Commitment Fee
IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee
317000
celu Issuance Of Common Stock Relating To Debt Extension And Commitment Fee
IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee
712000
celu Discounts Arising From Rwi Loan Arrangement Related Party
DiscountsArisingFromRWILoanArrangementRelatedParty
2151000
celu Fair Value Of Warrant Modification For Professional Services
FairValueOfWarrantModificationForProfessionalServices
403000
celu Change In Fair Value Of Contingent Stock Consideration
ChangeInFairValueOfContingentStockConsideration
-159000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3908000
celu Change In Fair Value Of Debt
ChangeInFairValueOfDebt
694000
celu Change In Fair Value Of Debt
ChangeInFairValueOfDebt
354000
celu Non Cash Interest Expense
NonCashInterestExpense
3217000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
285000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-2012000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1054000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
118000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-5653000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1605000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-109000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2179000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1312000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6754000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
7237000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1533000
celu Accrued Research Development Software
AccruedResearchDevelopmentSoftware
3500000
celu Accrued Research Development Software
AccruedResearchDevelopmentSoftware
-24161000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
274000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
172000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
312000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1065000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7995000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34344000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
105000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
468000
celu Proceeds From Sanuwave Convertible Note
ProceedsFromSanuwaveConvertibleNote
-2175000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2070000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3468000
celu Proceeds From Warrants And Short Term Debt Related Parties
ProceedsFromWarrantsAndShortTermDebtRelatedParties
15000000
celu Proceeds From Warrants And Short Term Debt Related Parties
ProceedsFromWarrantsAndShortTermDebtRelatedParties
18369000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
304000
celu Repayments Of Short Term Debt Unaffiliated
RepaymentsOfShortTermDebtUnaffiliated
17374000
celu Repayments Of Short Term Debt Unaffiliated
RepaymentsOfShortTermDebtUnaffiliated
16811000
celu Proceeds From Short Term Debt Unaffiliated
ProceedsFromShortTermDebtUnaffiliated
2993000
celu Proceeds From Short Term Debt Unaffiliated
ProceedsFromShortTermDebtUnaffiliated
2000000
celu Payment Of Sepa Commitment Fee
PaymentOfSepaCommitmentFee
25000
celu Repayments Of Short Term Debt Related Party
RepaymentsOfShortTermDebtRelatedParty
106000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6000000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
12750000
celu Proceeds From The Sale Of Common Stock In Atm Offering
ProceedsFromTheSaleOfCommonStockInAtmOffering
136000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1553000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
430000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
87000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6058000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24108000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
133000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13704000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10163000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28802000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10296000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15098000
us-gaap Interest Paid Net
InterestPaidNet
144000
us-gaap Interest Paid Net
InterestPaidNet
1073000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
56000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
752000
celu Modification Of Cv Starr Warrants In Connection With Forbearance
ModificationOfCVStarrWarrantsInConnectionWithForbearance
51000
celu Reduction Of Right Of Use Assets And Associated Lease Liability Due To Lease Modification
ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification
-2083000
celu Issuance Of Rwi Warrants In Connection With Forbearance
IssuanceOfRwiWarrantsInConnectionWithForbearance
1162000
celu Issuance Of Warrants On Senior Secured Bridge Loan
IssuanceOfWarrantsOnSeniorSecuredBridgeLoan
2002000
celu Reclassified From Warrant Liability To Additional Paid In Capital
ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital
2970000
celu Pipe Related Costs Included In Accrued Expenses
PIPERelatedCostsIncludedInAccruedExpenses
-69000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
4599000
celu Interest Accrued On Senior Secured Loans Within Long Term Debt Related Parties
InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties
-1229000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-08-29
us-gaap Operating Income Loss
OperatingIncomeLoss
-29078000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7995000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-886390000
CY2024Q3 celu Short Term Debt Gross
ShortTermDebtGross
46050000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, assumptions related to the Company’s goodwill and intangible asset impairment assessments, determination of incremental borrowing rates, accrual of research and development expenses, and the valuations of inventory, contingent consideration, short-term debt, stock options and stock warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p>
celu Instrument Specific Credit Risk Loss
InstrumentSpecificCreditRiskLoss
2000
celu Instrument Specific Credit Risk Income
InstrumentSpecificCreditRiskIncome
2541000
celu Accumulated Other Comprehensive Income To Other Expense Upon Short Term Debt Conversion
AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion
155000
celu Income Loss From Allocated To Warrants
IncomeLossFromAllocatedToWarrants
0
celu Income Loss From Allocated To Warrants
IncomeLossFromAllocatedToWarrants
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15929600
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13740797
CY2024Q3 celu Number Of Business Segments
NumberOfBusinessSegments
3
celu Number Of Business Segments
NumberOfBusinessSegments
3
CY2023Q3 celu Number Of Business Segments
NumberOfBusinessSegments
3
celu Number Of Business Segments
NumberOfBusinessSegments
3
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Allowance for Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With the adoption of ASU 2016-13 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments — Credit Losses,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as noted below, the Company recognizes credit losses based on forward-looking current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Customers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and restricted cash, and accounts receivable. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United States. As of September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, two of the Company's customers, each of which individually comprised at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, represented an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company's outstanding gross accounts receivable. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, two of the Company's customers, each of which individually comprised at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, represented an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company's outstanding gross accounts receivable. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had one customer that provided for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenue, respectively. The Company had no customers that individual comprised at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenue and one customer that provided for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenue during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended September 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain prior period amounts have been reclassified to conform with current year presentation. On the condensed consolidated balance sheets, short-term debt - Yorkville and other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related party and short-term debt - related parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 7 for further information.</span></p>
CY2024Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2024Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2023-01-01
CY2024Q3 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1606000
CY2024Q3 celu Contingent Stock Consideration
ContingentStockConsideration
27000
CY2024Q3 us-gaap Shortterm Debt Fair Value
ShorttermDebtFairValue
3695000
CY2024Q3 celu Warrant Liability Registered Direct Warrants Two
WarrantLiabilityRegisteredDirectWarrantsTwo
1748000
CY2024Q3 celu Warrant Liability Registered Direct Warrants
WarrantLiabilityRegisteredDirectWarrants
1670000
CY2024Q3 celu Warrant Liability Private Investment In Public Equity Warrants
WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
809000
CY2024Q3 celu Warrant Liability Sponsor Warrants
WarrantLiabilitySponsorWarrants
32000
CY2024Q3 celu Warrant Liability Public Warrants
WarrantLiabilityPublicWarrants
144000
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
9731000
CY2023Q4 celu Convertible Note Receivable
ConvertibleNoteReceivable
2072000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2072000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1606000
CY2023Q4 celu Contingent Stock Consideration
ContingentStockConsideration
27000
CY2023Q4 us-gaap Shortterm Debt Fair Value
ShorttermDebtFairValue
17223000
CY2023Q4 celu Warrant Liability Registered Direct Warrants Two
WarrantLiabilityRegisteredDirectWarrantsTwo
1529000
CY2023Q4 celu Warrant Liability Registered Direct Warrants
WarrantLiabilityRegisteredDirectWarrants
1487000
CY2023Q4 celu Warrant Liability Private Investment In Public Equity Warrants
WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
708000
CY2023Q4 celu Warrant Liability Sponsor Warrants
WarrantLiabilitySponsorWarrants
60000
CY2023Q4 celu Warrant Liability Public Warrants
WarrantLiabilityPublicWarrants
575000
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
23215000
celu Fair Value Assets Level One To Level Two Transfers Amount During Period
FairValueAssetsLevelOneToLevelTwoTransfersAmountDuringPeriod
0
celu Fair Value Assets Level Two To Level One Transfers Amount During Period
FairValueAssetsLevelTwoToLevelOneTransfersAmountDuringPeriod
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
celu Fair Value Assets Level One To Level Two Transfers Amount During Period
FairValueAssetsLevelOneToLevelTwoTransfersAmountDuringPeriod
0
celu Fair Value Assets Level Two To Level One Transfers Amount During Period
FairValueAssetsLevelTwoToLevelOneTransfersAmountDuringPeriod
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q4 celu Face Value Of Notes Receivable
FaceValueOfNotesReceivable
4000000
CY2023Q4 celu Valuation Model That Relate To Sanuwave Common Stock
ValuationModelThatRelateToSanuwaveCommonStock
0.23
CY2023Q4 celu Fair Value Net Assets Liability
FairValueNetAssetsLiability
3784000
celu Bridge Loan And Warrant Issuance Tranche Two
BridgeLoanAndWarrantIssuanceTrancheTwo
1858000
celu Gain Loss Recognized In Earnings From Change In Fair Values
GainLossRecognizedInEarningsFromChangeInFairValues
1587000
CY2024Q3 celu Reclassification Of Warrants From Liability Classified To Equity Classified
ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
-2970000
CY2024Q3 celu Fair Value Net Assets Liability
FairValueNetAssetsLiability
4259000
CY2024Q3 celu Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
42000
CY2023Q4 celu Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
3081000
CY2024Q3 celu Inventory Work In Progress Current And Noncurrent
InventoryWorkInProgressCurrentAndNoncurrent
10284000
CY2023Q4 celu Inventory Work In Progress Current And Noncurrent
InventoryWorkInProgressCurrentAndNoncurrent
10696000
CY2024Q3 celu Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
8720000
CY2023Q4 celu Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
10922000
CY2024Q3 celu Inventory Gross Current And Noncurrent
InventoryGrossCurrentAndNoncurrent
19046000
CY2023Q4 celu Inventory Gross Current And Noncurrent
InventoryGrossCurrentAndNoncurrent
24699000
CY2024Q3 celu Inventory Reserve Current And Noncurrent
InventoryReserveCurrentAndNoncurrent
2239000
CY2023Q4 celu Inventory Reserve Current And Noncurrent
InventoryReserveCurrentAndNoncurrent
2289000
CY2024Q3 celu Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
16807000
CY2023Q4 celu Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
22410000
CY2024Q3 us-gaap Inventory Net
InventoryNet
3963000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5753000
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
12844000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
16657000
CY2024Q3 celu Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
16807000
CY2023Q4 celu Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
22410000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
95155000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
95106000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31947000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27278000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
63208000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67828000
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1519000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1790000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4669000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5388000
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
82714000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
112347000
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
23993000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
23993000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
15069000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13692000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8924000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10301000
CY2024Q3 celu Acquired Product Rights
AcquiredProductRights
700000
CY2023Q4 celu Acquired Product Rights
AcquiredProductRights
700000
celu Indefinite Lived Intangible Assets Amortization Method
IndefiniteLivedIntangibleAssetsAmortizationMethod
indefinite
CY2023 celu Indefinite Lived Intangible Assets Amortization Method
IndefiniteLivedIntangibleAssetsAmortizationMethod
indefinite
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9624000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11001000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
375000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
553000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1377000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1640000
CY2024Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2023Q4 celu Other Short Term Debt
OtherShortTermDebt
2108000
CY2024Q3 celu Short Term Debt Unaffiliated
ShortTermDebtUnaffiliated
3695000
CY2023Q4 celu Short Term Debt Unaffiliated
ShortTermDebtUnaffiliated
19331000
CY2024Q3 celu Short Term Debt Related Parties
ShortTermDebtRelatedParties
38915000
CY2023Q4 celu Short Term Debt Related Parties
ShortTermDebtRelatedParties
19909000
CY2024Q3 us-gaap Debt Current
DebtCurrent
42610000
CY2023Q4 us-gaap Debt Current
DebtCurrent
39240000
CY2023Q2 celu Discount On Warrant Amount
DiscountOnWarrantAmount
2151000
CY2024Q3 celu Operating Leases Rent Expense
OperatingLeasesRentExpense
1114000
CY2023Q3 celu Operating Leases Rent Expense
OperatingLeasesRentExpense
892000
celu Operating Leases Rent Expense
OperatingLeasesRentExpense
3333000
celu Operating Leases Rent Expense
OperatingLeasesRentExpense
2687000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
978000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
759000
us-gaap Operating Lease Cost
OperatingLeaseCost
2933000
us-gaap Operating Lease Cost
OperatingLeaseCost
2278000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
348000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
320000
us-gaap Variable Lease Cost
VariableLeaseCost
1026000
us-gaap Variable Lease Cost
VariableLeaseCost
911000
CY2024Q3 us-gaap Lease Cost
LeaseCost
1326000
CY2023Q3 us-gaap Lease Cost
LeaseCost
1079000
us-gaap Lease Cost
LeaseCost
3959000
us-gaap Lease Cost
LeaseCost
3189000
us-gaap Operating Lease Payments
OperatingLeasePayments
2534000
us-gaap Operating Lease Payments
OperatingLeasePayments
2168000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
845000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3452000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3526000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3599000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3673000
CY2024Q3 celu Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
84568000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
99663000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
73212000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
26451000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P21Y6M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1424
CY2024Q3 celu Accrued Research And Development Software
AccruedResearchAndDevelopmentSoftware
0
CY2023Q4 celu Accrued Research And Development Software
AccruedResearchAndDevelopmentSoftware
3500000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
common stock are entitled to one vote per share
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
402000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
402000
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
6.5
CY2023Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6000000
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.5
CY2023Q2 celu Warrant Expiration Term
WarrantExpirationTerm
P5Y
CY2023Q2 celu Debt Instrument Payment
DebtInstrumentPayment
5505000
CY2023Q2 celu Fair Value Net Assets Liability
FairValueNetAssetsLiability
4280000
CY2023Q2 celu Additional Warrant Liability
AdditionalWarrantLiability
1389000
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.5
CY2023Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3000000
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.5
CY2023Q3 celu Warrant Expiration Term
WarrantExpirationTerm
P5Y
CY2023Q3 celu Debt Instrument Payment
DebtInstrumentPayment
2740000
CY2023Q3 celu Fair Value Net Assets Liability
FairValueNetAssetsLiability
2645000
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
892856
CY2023Q3 celu Reduced Exercise Price
ReducedExercisePrice
3.5
CY2023Q3 celu Warrant Liability
WarrantLiability
511000
CY2024Q1 celu Daily Interest Accruing Rate
DailyInterestAccruingRate
0.18
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10905901
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.045
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.041
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.108
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.865
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.39
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2672000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3598000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8628000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11442000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9296000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3786000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36088000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10659000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6020000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4492000
celu Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue
ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue
3931000
celu Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue
ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue
4579000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
3619000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
3514000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6332000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5557000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3736000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3818000
celu Contract With Customer Liability Recognition Of Unearned Revenue
ContractWithCustomerLiabilityRecognitionOfUnearnedRevenue
2271000
CY2023Q1 celu Contract With Customer Liability Recognition Of Unearned Revenue
ContractWithCustomerLiabilityRecognitionOfUnearnedRevenue
2271000
CY2023Q4 celu License Fee Payment
LicenseFeePayment
300000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3
CY2024Q3 us-gaap Assets
Assets
128840000
CY2023Q4 us-gaap Assets
Assets
143889000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9296000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
3883000
CY2024Q3 us-gaap Direct Operating Costs
DirectOperatingCosts
16565000
CY2024Q3 celu Segment Contribution
SegmentContribution
-11152000
CY2024Q3 celu Indirect Expenses
IndirectExpenses
375000
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11527000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3786000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
3602000
CY2023Q3 us-gaap Direct Operating Costs
DirectOperatingCosts
16212000
CY2023Q3 celu Segment Contribution
SegmentContribution
-16028000
CY2023Q3 celu Indirect Expenses
IndirectExpenses
83228000
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-99256000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36088000
us-gaap Cost Of Revenue
CostOfRevenue
7646000
us-gaap Direct Operating Costs
DirectOperatingCosts
56143000
celu Segment Contribution
SegmentContribution
-27701000
celu Indirect Expenses
IndirectExpenses
1377000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-29078000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10659000
us-gaap Cost Of Revenue
CostOfRevenue
6407000
us-gaap Direct Operating Costs
DirectOperatingCosts
92565000
celu Segment Contribution
SegmentContribution
-88313000
celu Indirect Expenses
IndirectExpenses
117289000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-205602000
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-133799-index-headers.html Edgar Link pending
0000950170-24-133799-index.html Edgar Link pending
0000950170-24-133799.txt Edgar Link pending
0000950170-24-133799-xbrl.zip Edgar Link pending
celu-20240930.htm Edgar Link pending
celu-20240930.xsd Edgar Link pending
celu-ex31_1.htm Edgar Link pending
celu-ex31_2.htm Edgar Link pending
celu-ex32_1.htm Edgar Link pending
celu-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
celu-20240930_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending